Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130312 · ClinicalTrials.gov registry record · Phase 4
Effect of Sulodexide in Overt Diabetic Nephropathy
A Phase 4 study, sponsored by Keryx Biopharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 968
- Enrollment target
NCT00130312 is a Phase 4 study that was terminated before completion, run by Keryx Biopharmaceuticals. The registered enrollment target is 968 participants.
The verdict
NCT00130312, a Phase 4 study, was terminated before completion, sponsored by Keryx Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 968 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether sulodexide is effective in slowing or preventing the progression of diabetic kidney disease.
Interventions
- DRUG Placebo
- DRUG Sulodexide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 968 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130312
The ClinicalTrials.gov registry entry for NCT00130312 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 968 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keryx Biopharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00130312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130312 about?
NCT00130312 is a clinical study titled "Effect of Sulodexide in Overt Diabetic Nephropathy". The purpose of this study is to determine whether sulodexide is effective in slowing or preventing the progression of diabetic kidney disease.
What is the current status of trial NCT00130312?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 968 participants. The study started on 2005-08. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00130312?
The interventions under investigation include: Placebo (DRUG), Sulodexide (DRUG).
Who is sponsoring clinical trial NCT00130312?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.